The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

This report provides all the information you require to better understand Alcon and its partnering interests and activities over the past seven years. Read the full story

Alcon is paying ThromboGenics €75 million to take over commercialization of ocriplasmin in all markets outside the U.S. ThromboGenics has completed a clinical development program that included two successful Phase III studies that have shown that ocriplasmin could play an important role in treating symptomatic vitreomacular adhesion (VMA) including macular hole.  Read the full story

In a deal potentially worth $493 million, Alcon has obtained global (excluding US) marketing rights to ThromboGenics ocirplasmin, a potential treatment for symptomatic vitreomacular adhesion (VMA) including macular hole Read the full story

Deal making on the up in the past week, with major deals announced by GSK, Alcon, Shire and Asahi Kasei Read the full story

Alcon, a global leader in eye care, , is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Alcon has selected the Bruker ContourGT-X8 Optical Surface Profiler to provide non-destructive, non-contact reference metrology for critical dimensioning and 3D characterization of Alcon’s current and next-generation intra-ocular lenses (IOLs).  Read the full story

After almost a year of wrangling with recalcitrant minority shareholders, Novartis has wrapped up a deal to buy the rest of eye care company Alcon. Novartis will still trade 2.8 shares of its own stock for each Alcon share--but it's adding enough cash to make sure Alcon shareholders get $168 worth of value each. Read the full story

Novartis has completed the purchase of 153 million shares of the leading eye care company Alcon in a deal worth $28.3 billion from Nestle Read the full story

Novartis AG and Nestlé S.A. have announced that they have completed the purchase and sale of approximately 156 million shares of Alcon, Inc. for US$28.3 billion in cash. Read the full story